We are live on ! Find out more
BNGO icon

Bionano Genomics

143 hedge funds and large institutions have $114M invested in Bionano Genomics in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 42 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more call options, than puts

Call options by funds: $2.82M | Put options by funds: $1.59M

0.01% more ownership

Funds ownership: 0.04%0.05% (+0.01%)

0% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 18

3% less funds holding

Funds holding: 148143 (-5)

12% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 42

39% less capital invested

Capital invested by funds: $187M → $114M (-$73.7M)

Holders
143
Holders Change
-5
Holders Change %
-3.38%
% of All Funds
2.41%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
37
Reduced
42
Closed
18
Calls
$2.82M
Puts
$1.59M
Net Calls
+$1.22M
Net Calls Change
-$552K

BNGO Hedge Fund Activity: Q2 2022 in Review

143 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q2 2022, worth a combined $114M — down 39% from $187M a quarter earlier.

Fund positioning in BNGO was balanced in Q2 2022: 18 funds opened new positions, 18 closed out, 37 added to existing stakes and 42 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $6.09M. The largest seller was Principal Financial Group, cutting an estimated $1.07M.

  • 143 institutional investors held Bionano Genomics (BNGO) as of Q2 2022, down from 148 in Q1 2022.
  • Funds reported $114M of Bionano Genomics stock for Q2 2022, down 39% quarter-over-quarter.
  • 18 funds opened new Bionano Genomics positions in Q2 2022 and 18 closed out, a net change of 0 holders.
  • The largest Bionano Genomics buyer in Q2 2022 was Renaissance Technologies, an estimated $6.09M added.
  • The largest Bionano Genomics seller in Q2 2022 was Principal Financial Group, an estimated $1.07M sold.

Based on aggregated 13F filings for Q2 2022.